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Abstract
Background: Little evidence is available for treatment of pediatric venous throm-
boembolism (VTE). Large randomized controlled trials are challenging in children. 
Current antithrombotic agents have many limitations, including nonoral administra-
tion and frequent monitoring. Edoxaban is an oral direct inhibitor of factor Xa without 
need of monitoring. In adults with VTE, edoxaban has shown to be effective and safe.
Objectives: The Edoxaban Hokusai VTE PEDIATRICS Study is an open-label, rand-
omized clinical trial to evaluate pharmacokinetics (PK) and pharmacodynamics (PD) 
of edoxaban and whether edoxaban is noninferior to standard of care in treatment 
of pediatric VTE.
Methods: A goal of 274 patients will be recruited in 5 age categories. A multidose PK/
PD assessment on day 5 in the first 12 patients of each age group is incorporated into 
this study. The primary composite efficacy outcome comprises symptomatic recur-
rent VTE, death due to VTE, and no change or extension of thrombotic burden. The 
principal safety end point is a combination of major and clinically relevant nonmajor 
bleeding. PK end points include apparent systemic clearance and volume of distribu-
tion of edoxaban. PD end points include prothrombin time, activated partial throm-
boplastin time, and anti-factor Xa level for the edoxaban treatment arm.
Results: To increase feasibility, the multidose PK/PD study is integrated in the phase 
3 trial. In addition, thrombotic burden, which is a prognostic factor for post throm-
botic syndrome in children, is one of the components of the primary composite ef-
ficacy outcome.
Conclusion: This study will increase the level of evidence for treatment in pediatric 
VTE.
K E Y W O R D S
child, edoxaban, feasibility, standard of care, venous thromboembolism
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Essentials
• All anticoagulant regimens currently used in pediatric patients have significant limitations.
• The study will evaluate efficacy and safety of edoxaban compared to standard of care in children.
• Multidose pharmacokinetics/pharmacodynamics study is integrated in phase 3 study to enhance feasibility.
• Feasibility is further increased by including thrombotic burden in composite efficacy outcome.
1  | INTRODUCTION
Venous thromboembolism (VTE) is increasingly diagnosed in pedi-
atric patients.1 The clinical presentation of pediatric VTE includes 
catheter-related thrombosis, pulmonary embolism, and deep vein 
thrombosis. In contrast to adults, most children have ≥1 clinical risk 
factors.2
Pediatric VTE is of clinical importance as it is associated with 
mortality and morbidity, including recurrent VTE, thrombotic bur-
den and postthrombotic symptoms. Mortality as result of throm-
bosis is reported to be between 0% and 2.2%.3,4 In the REVIVE 
trial, a randomized controlled trial comparing low molecular-weight 
heparin (LMWH) with unfractionated heparin (UFH) and vitamin 
K antagonists (VKAs), recurrent VTE occurred in 5 of 40 patients 
(12.5%) and 2 of 36 patients (5.6%) in the standard-of-care (SOC) 
group (UFH/VKA) and in the LMWH group, respectively.4 Only few 
studies described thrombotic burden after antithrombotic treat-
ment in children. In the study of Kuhle et al,5 no change or extension 
of thrombotic burden occurred in 27 of 148 children (18.2%) after 
3 months of treatment with tinzaparin. The incidence of postthrom-
botic symptoms after pediatric VTE varied between 10% and 70%. 
A meta-analysis showed a mean frequency of 26% (95% confidence 
interval [CI], 23%-28%).6
At present, the majority of children with VTE are initially 
treated with LMWH or UFH, usually followed by LMWH or VKAs 
for a total of 3 months or longer.7 In some children, fondaparinux 
is used. All anticoagulant regimens currently used in pediatric pa-
tients have significant limitations. UFH is administered intrave-
nously and needs to be frequently monitored by anti–factor Xa or 
activated partial thromboplastin time (APTT). Additional difficul-
ties with UFH are the physiologically reduced levels of anthrom-
bin in children as well as nonspecific binding to plasma proteins, 
both of which decrease the effectiveness of UFH.8 LMWH and 
fondaparinux are administered by subcutaneous injections. VKAs 
have a narrow therapeutic index, unpredictable pharmacologic 
response, and multiple food and drug interactions, and therefore 
require frequent monitoring. In addition, administration of VKAs 
in young children is challenging due to lack of a commercially avail-
able liquid formulation.
Direct oral anticoagulants (DOACs) may overcome many of these 
limitations for pediatric patients. DOACs can be administered orally, 
are antithrombin independent, have a rapid onset and offset of ac-
tion, few drug and food interactions, and predictable pharmacoki-
netics (PK) with no need of routine monitoring for anticoagulation 
activity. Drawbacks of DOACs might be heavy menstrual bleed-
ing, which seemed to occur more often with DOACs as compared 
with other anticoagulants and lack of adherence in adolescents.9 
Recently, 2 phase 3 DOAC trials for pediatric VTE have been pub-
lished. The rivaroxaban phase 3 study showed that rivaroxaban 
was as safe and effective as standard anticoagulants in children 
with VTE.10 A prospective cohort study revealed that dabigatran 
showed a favorable safety profile for secondary VTE prevention in 
children between 3 months and 18 years old with persistent VTE 
risk factor(s).11
Edoxaban is, as rivaroxaban, an oral, direct, specific inhibi-
tor of activated factor X (FX). The PK profile of edoxaban when 
compared to other DOACs offers several potential advantages.12 
Notably, the rapid peak plasma concentration, low cytochrome 
P450 metabolism, limited protein binding, and linear PK are es-
pecially relevant for use in pediatric VTE patients, which often 
take numerous other concomitant medications. After initial hep-
arin, edoxaban therapy was noninferior to warfarin in adults with 
VTE, and adults treated with edoxaban have fewer major or clin-
ically significant bleeding complications.13 The pediatric investi-
gational plan (PIP) of edoxaban starts with a phase 1, open-label 
study administering a single dose of either 30 or 60 mg of edox-
aban to pediatric patients who require anticoagulant therapy 
for VTE and aims to identify pediatric doses that approximate 
drug exposure observed in adults in children ages 0 to <18 years 
(NCT02303431). The Edoxaban Hokusai VTE PEDIATRICS Study 
is a phase 3, prospective, randomized clinical trial that aims to 
evaluate the efficacy and safety of edoxaban compared to SOC 
and describes multiple-dose PK and pharmacodynamics (PD) in 
children with a confirmed VTE (NCT02798471). The aim of this ar-
ticle is to describe the rationale and design of the phase 3 Hokusai 
VTE Pediatrics Study.
2  | STUDY OBJECTIVE AND HYPOTHESIS
The primary objective is to evaluate whether edoxaban after at least 
5 days of heparin (UFH, LMWH, or fondaparinux, with overlapping 
VKAs if given) is noninferior to SOC in the treatment of VTE in pedi-
atric patients with regard to the composite efficacy end point, in-
cluding symptomatic recurrent VTE, death as a result of VTE, and no 
change or extension in thrombotic burden, during the first 3-month 
treatment period. The secondary objectives are summarized in 
Table 1.
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3  | STUDY DESIGN
3.1 | Overview
This study is a phase 3, multinational, open-label, randomized, parallel-
group study, which will be conducted in about 150 sites in about 38 
countries. The trial is sponsored by Daichii Sankyo. The protocol was 
reviewed by institutional review boards at each participating center. 
Eligible participants or their parents/caretakers provide informed 
consent before randomization. The study is coordinated by a steer-
ing committee that provides clinical guidance on study implementa-
tion and study conduct. An independent data monitoring committee 
(IDMC) will monitor safety and outcomes of the participating patients 
and make recommendations to the steering committee at intervals 
during the study. A blinded independent clinical events committee 
(CEC) will review and adjudicate all safety and efficacy end points, 
such as all deaths, VTEs, thrombotic burden, bleeding events, and liver 
enzyme abnormalities.
3.2 | Patient population
The inclusion and exclusion criteria are listed in Table 2.
3.3 | Stratification and randomization
After patients are assessed for eligibility, they will be randomized 
in a 1:1 ratio into 1 of the 2 study arms: edoxaban treatment 
arm or SOC treatment arm. Randomization will be stratified by 
age cohorts and by region (United States/Canada, Europe, Asia/
Pacific, and rest of the world). The patients will be recruited in 
5 age categories: 12 to <18 years, 6 to <12 years, 2 to <6 years, 
6 months to <2 years and birth to <6 months. The patients will be 
enrolled from the oldest age cohort to the youngest age cohort.
3.4 | Edoxaban treatment arm
Edoxaban starting doses for each cohort will be selected based 
on edoxaban exposure for age-matched patients and safety data 
from the single-dose PK/PD study (NCT02303431), and on pop-
ulation-based PK. The first 12 patients of each age cohort (total 
of 60 patients) randomized to the edoxaban arm will participate 
in the multiple PK/PD assessment on day 5 (+3 days) (Figure 1). If 
this PK analysis confirms the exposure predictions and available 
safety data are satisfactory, further enrollment in the same age 
cohort will be allowed to start. Enrollment in the next younger age 
cohort is possible if PK and safety data analysis is performed on 
patients in the prior older age group in the phase 3 trial, and PK and 
safety data analysis is performed on patients in the next younger 
TA B L E  1   Secondary objectives
To compare edoxaban versus standard of care with regard to
Combination of major and CRNM bleeding
Combination of major and CRNM bleeding and symptomatic 
recurrent VTE and death as result of VTE
All bleedings
All-cause mortality
Individual components of the composite efficacy outcome
Occurrence of DVT, catheter-related VTE, PE, sinovenous 
thrombosis
To characterize the multiple dose pharmacokinetics of edoxaban 
in pediatric patients on day 5 using population pharmacokinetic 
analysis
To evaluate the relationship between edoxaban exposure and 
safety and efficacy
To characterize the effect of edoxaban on biomarkers of 
coagulation, including PT, APTT, and anti-FXa
anti-FXa, anti–activated factor X; APTT, activated partial prothrombin 
time; CRNM, clinically relevant nonmajor; DVT, deep vein thrombosis; 
PE, pulmonary embolism; PT, prothrombin time; VTE, venous 
thromboembolic event.
TA B L E  2   Inclusion and exclusion criteria
Inclusion
1. All children between birth (38-wk gestational age) and <18 y with 
a radiologically confirmed VTE requiring anticoagulants for at 
least 90 d
2. At least 5 d of heparin (UFH, LMWH or fondaparinux, with 
overlapping VKAs if needed) prior to randomization
Exclusion
 1. Active bleeding or high risk of bleeding contraindicating 
treatment with anticoagulants
 2. Prior treatment with thrombolytic agents, thrombectomy, or 
insertion of a caval filter for the newly identified index VTE
 3. >10 d of heparin therapy and/or VKA with therapeutic effect 
prior to randomization
 4. Antiplatelet therapy except low-dose aspirin, defined as 
1-5 mg/kg/d (with maximum of 100 mg/d)
 5. Hepatic disease associated with coagulopathy leading to a 
clinically relevant bleeding risk (APTT > 50 s or INR > 0.2 not 
related to anticoagulation therapy) or ALT > 5 × the upper level 
of normal or total bilirubin > 2 × upper level of normal with 
direct bilirubin > 20% of the total at screening visit
 6. Glomerular filtration rate < 30% of normal for age and size as 
determined by the Schwartz formula
 7. Stage 2 hypertension defined as blood pressure systolic and/or 
diastolic confirmed > 99th percentile + 5 mmHg
 8. Thrombocytopenia < 50 × 109/L at screening visit
 9. Life expectancy less than the expected study duration (3 mo)
 10. Pregnancy or breastfeeding
 11. Any condition that, as judged by the investigator, would place 
the subject at increased risk of harm if he/she participated in the 
study
 12. Participation in another trial or treated with an experimental 
therapy with <30-d washout period
ALT, alanine transaminase; APTT, activated partial thromboplastin time; 
INR, International Normalized Ratio; LMWH, low-molecular-weight 
heparin; UFH, infractionated heparin; VKA, vitamin K antagonists; VTE, 
venous thromboembolism.
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age cohort in the single-dose PK/PD study. IDMC will review PK 
and safety data and approve the start of the next younger age co-
hort. Edoxaban dosages will be reduced for patients with moder-
ate renal impairments ≥30% to ≤50% of normal for the patient’s 
age and size at randomization as determined by the Schwartz 
formula, and for patients requiring concomitant administration of 
certain P-glycoprotein inhibitors. Children from 12 to <18 years 
will receive tablets, which may be crushed and served with apple-
sauce or water; all younger children will receive granules for oral 
suspension.
3.5 | Standard of care treatment arm
The SOC arm consists of LMWH, VKA, or fondaparinux according to 
the site SOC treatment regimen.
3.6 | Duration of study
The main treatment period is defined as the time from randomiza-
tion, until the end of month 3 of treatment. On discretion of the 
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TA B L E  3   Secondary end points
Efficacy end points Safety end points PK/PD end points
The individual components of the primary 
efficacy end point during the first 3-mo period
A combination of major and CRNM bleedings 
occurring during treatment + 3 d during the first 
3-mo period
PK: apparent systemic clearance and 
apparent volume of distribution
All-cause mortality from randomization to the 
last dose of study drug + 30 d
All bleeding episodes from the first to the last study 
drug dose + 30 d
PD: PT, APTT, anti–factor Xa for the 
edoxaban treatment arm
DVT, catheter-related thrombosis, PE, and 
cerebral sinus venous thrombosis events within 
and after the first 3-mo treatment period
A combination of major and CRNM bleedings from 
the first to the last study drug dose + 30 d
Note: The clinical outcome end point is a composite combination of major and CRNM bleedings and symptomatic recurrent VTE and death as result 
of VTE during the whole study period.
APTT, activated partial thromboplastin time; CRNM, clinically relevant nonmajor; DVT, deep vein thrombosis; PD, pharmacodynamics; PE, pulmonary 
embolism; PK, pharmacokinetics; PT, prothrombin time; VTE, venous thromboembolism.
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investigator, all patients may continue into the extension period for 
a maximum period of an additional 9 months using edoxaban.
3.7 | Study end points
The primary efficacy end point is a composite end point consisting of 
the incidence of symptomatic recurrent VTE, death as result of VTE, 
and no change or extension of thrombotic burden during the first 
3-month period. To assess the thrombotic burden, the same radio-
logic technique that is used at the enrollment of the patient will be 
used at the end of the observational period ± 3 days. All secondary 
end points are listed in Table 3. Bleeding complications are defined 
as recommended by the ISTH pediatric subcommittee.14 Menstrual 
bleeding resulting in a medical consultation and/or intervention will 
be classified as a minor bleeding event.
3.8 | Follow-up
In the main treatment period, all patients will return to the clinic 
monthly. All randomized patients including those who have discon-
tinued treatment will have an end-of-treatment assessment after 
3 months, which includes radiologic evaluation of the thrombotic 
burden. In the extension period, patients will be followed every 
3 months. After discontinuation of the study or after completing 
12 months of study treatment, a discontinuation study or month 12 
visit will be performed. Furthermore, all patients will have an end-
of-study safety follow-up visit 1 month after the last dose of study 
treatment.
3.9 | Sample size and statistical analysis
The sample size calculation is based on the statistical approach and 
results of the adult Hokusai-VTE study.13 In that study, a noninferior 
margin for the hazard ratio of 1.5 was used because of the high ef-
fectivity of the SOC therapy.15 The sample size of the pediatric study 
is event driven to collect approximately 68 overall primary efficacy 
events during the main treatment period. Assuming the edoxaban 
treatment group will observe a 24% reduction of the event rate com-
pared to SOC and a noninferiority margin of 1.5, the study will have 
about 80% of power to demonstrate noninferiority with α = .05 (2-
sided). Based on literature, we expect an incidence of composite pri-
mary efficacy endpoint of 28% in the SOC treatment arm during the 
main study period.4,16,17 As a consequence, 274 patients (137 in each 
treatment arm) need to be randomized to study drug treatment. An 
interim assessment of incidence rate of the composite efficacy end 
point in both treatment arms will take place after completion of the 
main treatment period by the first 140 patients. This will allow for 
adjustment of number of patients in the study if necessary.
The primary efficacy analysis will be based on a modi-
fied intention-to-treat (mITT) analysis set, and will include the 
primary composite outcome occurring from randomization up to 
3 months + 3 days from randomization. The mITT analysis set is de-
fined as all randomized patients receiving at least 1 dose of the study 
drug. Analyses will be based on the randomized treatment arm even 
if a patient accidentally received the inappropriate study drug. The 
time to the first event of the composite primary efficacy outcome 
will be analyzed using Cox’s proportional hazard regression model 
including treatment arm and age groups as covariates. Region is not 
included in this model as a covariate because some age groups by re-
gion may be very small due to the small sample size. The edoxaban-
to-SOC hazard ratio will be calculated with 95% CI based on this 
model. Edoxaban will be considered noninferior to SOC if the upper 
limit of the 95% CI is <1.5. If noninferiority of edoxaban is estab-
lished, edoxaban will be tested for superiority to SOC. Edoxaban will 
be considered superior if the upper limit of the 95% CI from above 
analysis is <1.0. The secondary efficacy outcomes will be analyzed 
using Cox’s proportional hazard model similar to the primary effi-
cacy analysis.
All patients who received 1 dose of study drug will be included 
in the safety analyses. These safety analyses will be based on the 
randomized treatment, unless a patient received the incorrect drug. 
Such a patient will be redirected to the appropriate treatment group. 
Safety end points will be compared between the 2 treatment groups, 
using a similar Cox’s proportional hazard model as described in the 
primary efficacy analysis.
4  | DISCUSSION
In the past few decades, it has become clear that performing 
randomized clinical trials in children with VTE is a challenging 
mission. Until recently, only a few clinical trials have been done 
and most of them closed early due to slow recruitment or were 
not powered for efficacy.4,18-20 The Kids-Dott study, investi-
gating the duration of anticoagulant therapy, started in March 
2008 and stopped inclusion only a few months ago.21 Multiple 
industry-sponsored phase 3 studies of DOACs are currently being 
performed or have just been completed, comprising treatment of 
pediatric VTE, prophylaxis of cardiac thrombosis, and prophylaxis 
of VTE.22 These trials provide important data, but most of them 
are not powered to demonstrate safety and efficacy. Several rea-
sons are responsible for the difficulty of performing large clini-
cal trials in pediatric VTE patients. The most important reason is 
the rarity of the disease.23,24 Although the incidence is increas-
ing, VTE remains infrequent in children, with incidence peaks in 
neonates and teenagers.1 Furthermore, in contrast to adults, VTE 
mainly occurs in sick children with multiple underlying diseases 
with various bleeding risks, and many concurrent medications. As 
a consequence, a large proportion of eligible patients with VTE 
are excluded from studies. Moreover, it remains difficult for par-
ents to give permission for study participation, especially when 
their children are young and very sick. Thus, pediatric VTE clini-
cal trials need to be executed in many centers all over the world. 
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This is reflected in all phase 3 studies of DOACs, which need to 
be performed at multiple centers around the world to include suf-
ficient pediatric patients (rivaroxaban, NCT02234843; apixaban, 
NCT02464969; dabigatran, NCT01895777).
The pediatric DOAC trials, including the Edoxaban Hokusai 
VTE PEDIATRICS Study, are the outcome of collaboration between 
pharmaceutical companies and academic experts in the field of 
pediatric thrombosis. To develop high-quality trials to increase 
the evidence of antithrombotic treatment in children with VTE, 
collaboration between both parties is needed. Pharmaceutical 
companies benefit from the knowledge of the academic pediatric 
thrombosis experts for the development of their PIPs, and in re-
turn they provide logistics and funding for the large, international 
trials.14 Very recently, the ISTH pediatric subcommittee has estab-
lished a task force for drug development in pediatric thrombosis 
to provide expert input into the development of industry-initiated 
studies and to create a trial network to perform both industry and 
academic studies under the umbrella of the International Pediatric 
Thrombosis Network.25
Two study design features increase the feasibility of the 
edoxaban PIP, including the phase 3 Edoxaban Hokusai VTE 
PEDIATRICS Study. First, multiple-dose PK/PD assessment was 
incorporated in the phase 3 trial to ease participation of patients 
in that part of the PIP. The first 12 patients of each age cohort 
of the randomized trial are included in the multidose PK/PD as-
sessment on the day of the fifth dose of edoxaban. Second, a 
composite efficacy outcome has been used. No change or pro-
gression of thrombotic burden after 3 months of treatment is one 
of the components of this composite efficacy outcome. In adult 
studies, clot-burden change has often been used as a surrogate 
end point for clinical anticoagulation trials. A systematic review 
of adult studies showed a predictive correlation between change 
in clot-burden and long-term clinical outcome.26 In the pediatric 
literature, the frequency of no change or progression of throm-
botic burden has been described to be about 18%.5,27,28 Lack of 
thrombus resolution is one of the prognostic factors for the devel-
opment of postthrombotic syndrome in children, which is a long-
term complication that occurs in about 26% of the children after 
leg or arm DVT.6 Therefore, it seems reasonable to use thrombotic 
burden as a surrogate outcome measure in this trial. It increases 
feasibility by decreasing the sample size.
One of the limitations of this trial is the open design. However, 
reported potential study end points will be reviewed by a panel of 
independent CEC adjudicators for confirmation while being blinded 
to the treatment arm. In children, it is unethical to use placebo sub-
cutaneous injections as a comparator of LMWH or to perform false 
International Normalized Ratio tests when patients are randomly 
assigned to edoxaban. Furthermore, the study patient group will be 
heterogeneous, including, among others, neonates and oncology pa-
tients with catheter-related thrombosis, children with cerebral sinus 
venous thrombosis or pulmonary embolism, and adolescents with 
estrogen-associated DVT. These neonates and children have diverse 
short-term and long-term complications and different risk-benefit 
ratios of anticoagulant treatment. Moreover, thrombotic burden 
is part of the composite outcome and may cause information bias. 
Comparing ultrasound images over time will be especially challeng-
ing. Ultrasonography will be done frequently by different radiolo-
gists. To ensure adequate adjudication of this end point, detailed 
instructions in obtaining images are provided to the study sites, and 
both initial and follow-up imaging are independently and blindly as-
sessed by the CEC.
In summary, randomized controlled anticoagulation trials are 
challenging in children. The Edoxaban Hokusai VTE PEDIATRICS 
Study incorporates multiple-dose PK/PD assessment in the phase 
3 trial and uses a composite efficacy outcome, including thrombotic 
burden, to increase feasibility of the trial. This study will provide use-
ful information, not only about the efficacy and safety of edoxaban 
in children with VTE, but also about these two study design features.
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BRIEF SUMMARY FOR GENERAL PUBLIC
All current anticoagulants have important limitations in children 
for treatment of venous thrombosis. Edoxaban is one of the new 
direct oral anticoagulants without need of monitoring. In adults 
with venous thrombosis, edoxaban has shown to be effective and 
safe. The Edoxaban Hokusai VTE PEDIATRICS Study will evaluate 
pharmacokinetics (PK) and pharmacodynamics (PD) of edoxaban 
and whether edoxaban is similar to standard of care in treatment of 
pediatric venous thrombosis. Performing randomized clinical trials in 
children with thrombosis is a challenging mission, mainly due to the 
rarity of the disease. To increase feasibility, the multiple-dose PK/
PD study is integrated in the phase 3 trial. In addition, thrombotic 
burden which is a prognostic factor for postthrombotic syndrome 
in children, is one of the components of the primary composite ef-
ficacy outcome.
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tion of multidose PK/PD study and thrombotic burden in composite 
efficacy outcome.
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